MED13

Across TCGA pan-cancer cohorts, MED13 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated MED13 data layer compared with 27 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MED13 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MED13 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and UCEC show a favorable association.

CCRCC, UCEC, and GBM are the cancer types where MED13 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	III,IV	0.814	0.203	<.001	32	view →
UCEC	DFS	Tertile	III,IV	1.000	0.232	.002	20	view →
GBM	DFS	Tertile	All	0.854	0.522	.019	5	view →
PDAC	OS	Median	II,III,IV	0.700	0.939	.027	5	view →
LUAD	DFS	Tertile	II,III,IV	0.973	0.754	.013	5	view →
HNSC	DFS	Quartile	All	0.686	1.000	.043	4	view →
LSCC	DFS	Median	All	0.612	0.868	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

MED13–CCRCC (OS)

Open the CCRCC breakdown →